This inventor holds 1 USPTO granted patent and 6 published patent applications. Top assignee: Civi Biopharma, Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: The Innovative Contributions of Charles Lester Shear
Introduction
Charles Lester Shear, an inventive mind based in Collegeville, Pennsylvania, has made noteworthy contributions to the field of biopharmaceuticals. Known for his dedication to advancing medical therapies, Shear holds a significant patent that targets cardiovascular health through innovative delivery methods.
Latest Patents
Shear's prominent patent, titled "Oral delivery of antisense conjugates targeting PCSK9," entails pharmaceutical compositions designed for oral administration. The invention primarily includes an antisense oligonucleotide known as CIVI 008, combined with an oral delivery agent, 5-CNAC. Furthermore, this patent describes a unique capsule formulation that integrates a dry blend of CIVI 008 and 5-CNAC, with the optional addition of a statin. This innovative approach has the potential to enhance the efficacy of treatments aimed at lowering cholesterol levels in patients.
Career Highlights
Charles Lester Shear currently serves at Civi Biopharma, Inc., where he has dedicated his expertise to pioneering new therapeutic options. His deep understanding of biochemistry and pharmaceuticals has positioned him as a vital contributor to the company's mission of improving patient outcomes through innovative drug delivery systems.
Collaborations
Shear collaborates with esteemed colleagues, including Henrik Oerum and Stewart Alwyn Noble. These partnerships have facilitated the exchange of ideas and fostered an environment of creativity, enabling impactful advancements in pharmaceutical research and development.
Conclusion
In summary, Charles Lester Shear's innovative work in oral delivery systems signifies a remarkable step forward in medical treatments targeting PCSK9. His contributions at Civi Biopharma, combined with his collaborations, highlight the importance of teamwork in driving scientific progress. As he continues to explore new avenues in biopharmaceutical innovation, Shear remains an inspiring figure in the field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile